CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 75 enrolled
Drug / intervention
Ramiprildrug
Likely dose
Ramipril 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03475186
NCT03475186Phase 2Completed
CompareCT.gov

A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy

Wake Forest University Health Sciences·interventional·Posted Mar 23, 2018·Updated Mar 13, 2026

In Brief

A Phase 2 clinical trial evaluating Ramipril for Glioblastoma and 3 related conditions. Completed, enrolled 75 participants across 423 sites in 2 countries.

Detailed Summary

This study is to determine if an oral drug called Ramipril can lower the chance of memory loss in patients with glioblastoma getting chemoradiation. Patients will take Ramipril during chemoradiation and continue until 4 months post-treatment. Memory loss will be assessed using several neurocognitive tests throughout the duration of the study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioblastoma, Radiotherapy; Complications, Cognitive Decline, Chemoradiation
CountriesGuam, United States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMar 23, 2018
Enrollment StartMar 25, 2019
Primary CompletionMar 25, 2025
TodayJul 2, 2026
Enrollment to primary: 6 yearsPosted 8.3 years ago

Interventions

Ramiprildrug

2.5 - 5 mg oral, 1x daily for 22 weeks